Date: 2014-09-23
Type of information: Nomination
Compound: chief scientific officer
Company: Transgene (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 23, 2014, Transgene announced the appointment of Eric Quéméneur, PhD as Executive Vice President in charge of Research and Development. In this position, he will lead all of the Company’s research activities, from discovery through pre-clinical. Dr. Quéméneur is a member of Transgene’s Management Committee. Eric Quéméneur has over 25 years of life sciences experience, including leading R&D efforts, building interdisciplinary teams and developing national and international partnerships. He joins Transgene from the French Atomic Energy Commission (CEA), where he worked for over 20 years in positions of increasing responsibility, most recently serving as Director, Research Programs and Industrial Partnerships in the Life Sciences Division. He has a strong scientific background in protein engineering, biomanufacturing technologies, toxicology, as well as bioanalytical development. He has authored nearly 80 articles published in international scientific journals. Dr. Quéméneur serves in a variety of advisory positions, including: Scientific Advisory Board member for recombinant vaccine production firm, Medicago Inc.; biotechnology business development advisor to Bertin Pharma and Bertin Technologies; and co-chair of the Radiobiology/Radiotoxicology programs at Areva. He has also been an administrator of CEA-I and ATI, two technology-oriented investment funds, and is a member of the international review panel for the Italian Ministry for Education, University and Research (MIUR). Dr. Quéméneur has a PhD in Biochemistry from the Claude Bernard University in Lyon, France.
Financial terms:
Latest news:
Is general: Yes
